Int J Family Med Prim Care | Volume 2, Issue 3 | Review Article | Open Access

What is Known and Don't Known about Current m-RNA Vaccines Anti-COVID-19 in the Experts' Opinions

Udristioiu A1*, Cojocaru M1 and Farmazon I3

1Titu Maiorescu University, Bucharest, Romania 2Laboratory Medicine, Bucharest, Romania

*Correspondance to: Udristioiu A 

Fulltext PDF


The patients with convalescent SARS-CoV-2 have a neutralizing antibody response that can be detected until 11 months after infection and is predominantly directed against the S protein, through which the virus binds to membrane receptors. The results revealed that neutralizing antibody responses in case of SARS-S may bring protection against SARS-CoV-2 infection. To ensure they have safety standards, COVID-19 vaccines were tested in large clinical trials. In these trials, a lot of people were recruited to assist to understand how the vaccines can offer public protection regardless races, ages, ethnicities or different medical conditions. World Health Organization (WHO) has chosen the best vaccine candidates, in order to develop fastest vaccine taking into account efficacy, safety standards, and provide them government support. Messenger RNA (mRNA) vaccines have the same efficacy and safety standards as any type of vaccines in the Europe and United States. Conclusion: The advantages and risks for immunocompromised patients who received a vaccine against SARS-CoV-2 should be considered from case to case, with discussion of the incidence of infection in the community. Vaccines are not a perfect solution. Other measures should be still needed to be practice like social distancing, hand washing, wearing a mask until public health.


ACE2 receptors; CRISPR-Cas12-13 technology; Messenger ARN; SARS-CoV-2 vaccine; Spike protein S


Udristioiu A, Cojocaru M, Farmazon I. What is Known and Don't Known about Current m-RNA Vaccines Anti- COVID-19 in the Experts' Opinions. Int J Fam Med Prim Care. 2021;2(3):1043.

Subscribe to Our Newsletter